Differential endothelial cell remodeling in Down syndrome and APP duplication drives distinct blood brain barrier dysfunction

Topic: Brain proteins, microglia and lab models

An extra copy of the amyloid precursor protein gene (APP) is present in Down syndrome (DS) and APP duplication (APPdup), increasing the risk of Alzheimer disease (AD) and cerebral amyloid angiopathy (CAA). However, we reported greater vascular Aβ deposition in APPdup than in DS with AD, suggesting that other triplicated chromosome 21 genes may mitigate CAA severity. We investigated endothelial cell (EC) function and blood brain barrier (BBB) integrity in DS and APPdup using human induced pluripotent stem cell-derived ECs (iECs), assessing their morphology, junctional proteins, Aβ peptide secretion, barrier function, and transcriptomic profiles. Both DS and APPdup iECs secreted more Aβ40 Aβ42 compared with their respective isogenic controls but exhibited distinct Aβ peptide profiles. DS iECs showed increased junctional protein expression and reduced permeability, whereas APPdup iECs displayed increased permeability. Transcriptomic analysis revealed extensive dysregulation in DS iECs, with enrichment of junctional, adhesion, angiogenic, immune, and apoptosis pathways, and reduced cell-cycle, proliferative, and membrane-targeting signatures. APPdup iECs showed milder changes, including impaired protein targeting and reduced adhesion-related pathways. Despite comparable APP dosage, DS iECs maintained greater junctional integrity and lower permeability than APPdup iECs, potentially contributing to differential CAA vulnerability. However, impaired proliferation and altered angiogenesis may reduce BBB resilience during ageing.

Key findings

• However, we reported greater vascular Aβ deposition in APPdup than in DS with AD, suggesting that other triplicated chromosome 21 genes may mitigate CAA severity.
• Both DS and APPdup iECs secreted more Aβ40 Aβ42 compared with their respective isogenic controls but exhibited distinct Aβ peptide profiles.
• Transcriptomic analysis revealed extensive dysregulation in DS iECs, with enrichment of junctional, adhesion, angiogenic, immune, and apoptosis pathways, and reduced cell-cycle, proliferative, and membrane-targeting signatures.

Study details

• Evidence strengthLow

Read the original

• DOI: 10.64898/2026.10.29.762815
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{valay2026-d4bf18aa,
  author  = {Valay, L. and Kasri, A. and Fontaine, V. and Camporesi, E. and Bigou, S. and Brinkmalm, G. and Piotrowska, D. and Dancette, L. and others},
  title   = {{Differential endothelial cell remodeling in Down syndrome and APP duplication drives distinct blood brain barrier dysfunction}},
  journal = {bioRxiv},
  year    = {2026},
  doi     = {10.64898/2026.10.29.762815},
  url     = {https://doi.org/10.64898/2026.10.29.762815}
}

Related studies in Down syndrome and Alzheimer's

• Modulation of blood-brain barrier permeability Journal of drug targeting · 1996-01-01 · usefulness score 37/100
• Type-I-interferon signaling drives microglial dysfunction and senescence in human iPSC models of Down syndrome and Alzheimer's disease Cell stem cell · 2022-07-01 · usefulness score 40/100
• APP Dosage and Extracellular Domain Variants Drive Distinct Defects in Neurogenesis modeled in Down Syndrome iPS cells bioRxiv · 2026-08-06 · usefulness score 16/100
• Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells The Journal of biological chemistry · 2009-06-19 · usefulness score 42/100
• Global differential expression of genes located in the Down Syndrome Critical Region in normal human brain Colombia medica (Cali, Colombia) · 2014-10-01 · usefulness score 32/100
• Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr682-phosphorylated APP βCTF Science advances · 2023-07-26 · usefulness score 50/100

Similar studies

• Modeling Down syndrome neurodevelopment with isogenic cerebral organoids 2022 · Down syndrome and Alzheimer's
• Reexpression of a developmentally regulated antigen in Down syndrome and Alzheimer disease 1988 · Down syndrome and Alzheimer's
• Oligodendrocyte Enriched Brain Organoids Reveal Impaired Oligodendroglial Maturation and Altered Neural Network Activity in Down Syndrome 2026 · Down syndrome and Alzheimer's
• Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome 2023 · Down syndrome and Alzheimer's
• Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology 2017 · Down syndrome and Alzheimer's
• A head-to-head comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials 2025 · Down syndrome and Alzheimer's

More on Down syndrome and Alzheimer's

• A review that covers this ground Oxidative stress and mitochondrial dysfunction in Down syndrome Advances in experimental medicine and biology · 2012-01-01 · usefulness score 41/100
• Newest in this subject Memory and Plasma pTau217 Refine Prognosis in Down Syndrome Annals of neurology · 2026-10-02 · Peer-reviewed · usefulness score 47/100
• Newest in this subject Tau extent is associated with lower cognition in Down syndrome-related Alzheimer's disease Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026-10-01 · Peer-reviewed · usefulness score 53/100

See all studies in Down syndrome and Alzheimer's →